2019
DOI: 10.1002/jia2.25267
|View full text |Cite
|
Sign up to set email alerts
|

Pursuing use of optimal formulations for paediatric HIV epidemic control – a look at the use of LPV/r oral pellets and oral granules

Abstract: Introduction Despite a significant reduction in mother‐to‐child transmission of HIV, an estimated 180,000 children were infected with HIV in 2017, and only 52% of children under 15 years of age living with HIV (CLHIV) are on life‐saving antiretroviral therapy (ART). Without effective treatment, half of CLHIV die before the age of two years and only one in five survives to five years of age. Discussion Over the past four years, the United States Food and Drug Administrat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
10
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
5
1
1

Relationship

1
6

Authors

Journals

citations
Cited by 10 publications
(10 citation statements)
references
References 15 publications
0
10
0
Order By: Relevance
“…This allows for greater convenience than twice‐daily LPV/r and reduces pill burden [8]. In addition, paediatric DTG overcomes other disadvantages of LPV/r formulations: LPV/r granules and pellets require additional training to ensure appropriate adherence [13]; LPV/r oral solution has poor palatability and requires consistent cold chain until dispensed [13]; and the LPV/r heat‐stable tablet cannot be cut, crushed, chewed, or dissolved [13], precluding the use of this formulation in young CLHIV.…”
mentioning
confidence: 99%
“…This allows for greater convenience than twice‐daily LPV/r and reduces pill burden [8]. In addition, paediatric DTG overcomes other disadvantages of LPV/r formulations: LPV/r granules and pellets require additional training to ensure appropriate adherence [13]; LPV/r oral solution has poor palatability and requires consistent cold chain until dispensed [13]; and the LPV/r heat‐stable tablet cannot be cut, crushed, chewed, or dissolved [13], precluding the use of this formulation in young CLHIV.…”
mentioning
confidence: 99%
“…Additionally, liquid formulations need cold chain storage, which can be an obstacle in resource limited settings [9]. In 2015, the USA food and drug formulation tentatively approved LPV/r oral pellets, and subsequently approved LPV/r oral granules in August 2018 [24]. The pellet and granule formulations offer advantages over the liquid form as they are easy to administer across dosing ranges, easy to store and transport, and palatable.…”
Section: Antiretroviral Therapy Challenges In Children and Adolescentsmentioning
confidence: 99%
“…The pellet and granule formulations offer advantages over the liquid form as they are easy to administer across dosing ranges, easy to store and transport, and palatable. However, there has been a slow uptake of these formulations in low and middle-income countries due to limited manufacturing capacity, making policy makers reluctant to transition to LPV/r based ART regimens [24].…”
Section: Antiretroviral Therapy Challenges In Children and Adolescentsmentioning
confidence: 99%
“…However, the lack of data remained an obstacle for reliable evaluation of the treatment effect of therapies attempted. There are several on-going clinical trials, whose completion, however, requires more time and resources with uncertain [13][14] . Ribavirin is an antiviral drug mainly used for viral pneumonia and bronchitis caused by respiratory syncytial virus 15 .…”
Section: Introductionmentioning
confidence: 99%
“…In addition, other antiviral drugs including Oseltamivir, Ganciclovir, Favipiravir and Remdesivir have also been used in clinical practice. Lopinavir/Ritonavir is commonly used in combination with other antiretroviral drugs to treat HIV infection [13][14] . Ribavirin is an antiviral drug mainly used for viral pneumonia and bronchitis caused by respiratory syncytial virus 15 .…”
Section: Introductionmentioning
confidence: 99%